ONYX PHARMACEUTICALS INC 4
4 · ONYX PHARMACEUTICALS INC · Filed Aug 14, 2007
Insider Transaction Report
Form 4
KENNEY EDWARD F
EVP, Chief Business Officer
Transactions
- Sale
Common Stock
2007-08-13$31.94/sh−100$3,194→ 41,000 total - Sale
Common Stock
2007-08-13$31.88/sh−300$9,564→ 40,000 total - Sale
Common Stock
2007-08-13$31.83/sh−1,500$47,745→ 37,700 total - Sale
Common Stock
2007-08-13$31.86/sh−5,200$165,672→ 31,000 total - Sale
Common Stock
2007-08-13$32.02/sh−200$6,404→ 29,400 total - Sale
Common Stock
2007-08-13$32.01/sh−900$28,809→ 27,800 total - Exercise/Conversion
Common Stock
2007-08-13$20.81/sh−16,000$332,960→ 43,500 total - Sale
Common Stock
2007-08-13$31.89/sh−800$25,512→ 41,100 total - Sale
Common Stock
2007-08-13$31.90/sh−1,600$51,040→ 41,900 total - Sale
Common Stock
2007-08-13$31.85/sh−700$22,295→ 40,300 total - Sale
Common Stock
2007-08-13$31.95/sh−500$15,975→ 39,500 total - Exercise/Conversion
Stock Option (Right to Buy)
2007-08-13−16,000→ 34,000 totalExercise: $20.81Exp: 2015-08-31→ Common Stock (16,000 underlying)
Footnotes (1)
- [F1]The shares become exercisable at a rate of 1/48th per month over a period of 48 months from the date of grant.